DDInter1763 DDInter997
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Temsirolimus {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Temsirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Temsirolimus {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Temsirolimus {u} (Compound) causes {v} (Side Effect) Bilirubin total increased
Bilirubin total increased {u} (Side Effect) is caused by {v} (Compound) Dolutegravir
Dolutegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Temsirolimus {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) interacts with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Temsirolimus {u} (Compound) causes {v} (Side Effect) Bilirubin total increased
Bilirubin total increased {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Temsirolimus (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Temsirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Temsirolimus (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Temsirolimus (Compound) causes Bilirubin total increased (Side Effect) and Bilirubin total increased (Side Effect) is caused by Dolutegravir (Compound) and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Temsirolimus (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) interacts with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Temsirolimus (Compound) causes Bilirubin total increased (Side Effect) and Bilirubin total increased (Side Effect) is caused by Rilpivirine (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor